TLSA - Latest News
Tiziana Life Sciences Ltd (TLSA), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $66.8M. Beta to the broader market is 0.45.
The article list below shows the most recent TLSA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TLSA Headlines
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
proactiveinvestors.com - Sep 30, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
proactiveinvestors.com - Sep 28, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial i
Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
proactiveinvestors.com - Sep 21, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluati
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
proactiveinvestors.com - Sep 17, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC)
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
proactiveinvestors.com - Sep 3, 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating
How News Affects TLSA Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TLSA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TLSA news questions
- What is the latest TLSA news headline?
- The most recent TLSA headline (Sep 30, 2026) is "Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TLSA news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TLSA news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TLSA options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.